JKJohn E. Kirsch

John E. Kirsch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John E. Kirsch has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Relationship of Inferior Frontal Sulcal Hyperintensities with Amyloid-Related Imaging Abnormalities

    by Saurabh Rohatgi, Nima Omid-Fard, Shenghua Zhu, Rafael Eduardo Martinez Imbett, Jeremy N. Ford, Thomas P. Dowling, John E. Kirsch, Javier M. Romero

    Anti-amyloid immunotherapies used to treat Alzheimer's disease (AD) are often associated with amyloid-related imaging abnormalities (ARIA). We aim to indirectly assess glymphatic function by using inferior frontal sulcal hyperintensity (IFSH) as a biomarker in patients receiving anti-amyloid therapy, both with and without ARIA, as well as in healthy controls. We hypothesize that patients who develop ARIA will have higher IFSH scores than non-ARIA patients and healthy controls. Eligible AD patients who received anti-amyloid treatment were included in our retrospectively collected dataset. Only scans performed at 3T were used. Inter-rater reliability was evaluated and statistical analyses of IFSH scores and demographic data were performed to compare between groups. Additionally, within-subject analysis was used to compare the baseline and ARIA scans. Significance set at P < 0.05. A total of 104 patients were selected based on the study criteria, of whom 60 had a clinical diagnosis of dementia. 36 patients developed ARIA, while 24 did not develop ARIA. 23 were age-matched healthy controls, and 21 were young healthy controls. Inter-rater reliability between the two readers was concordant when using quadratic weights appropriate for ordinal data (κ (w) = 0. 91, 95% CI 0.86-0.95). IFSH was significantly higher in the older age cohorts compared to young healthy controls (median 3.5 [IQR 2.5-5] versus 0 [0-1], P<0.001), with no significant difference between the dementia and healthy elderly groups (3.25 [3-4.875] versus 3.5 [2.5-5]). Among dementia patients on anti-amyloid therapy, significantly higher IFSH was observed in ARIA patients (at time of ARIA scan) compared to their non-ARIA counterparts (3.75 [3-5] versus 3 [2-4], P= 0.04). There was no significant difference in IFSH score between baseline and ARIA scans (P = 0.16). IFSH was higher among dementia patients on anti-amyloid therapy with ARIA than among their non-ARIA counterparts. This supports its role as a potential biomarker of glymphatic dysfunction, although its utility on an individual basis is limited. Future prospective studies could benefit from incorporating IFSH as a variable, particularly if glymphatic therapies become a reality.

  • Open Access

    In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy

    by Hilde van Den Brink, Mariel G. Kozberg, Nazanin Makkinejad, John E. Kirsch, Michael J. Thrippleton, Thijs W. van Harten, Sabine Voigt, Whitney M. Freeze, Matthias J.P. Van Osch, Anand Viswanathan, et al.

    Blood-brain barrier (BBB) leakage may be an early step in the pathophysiology of cerebral amyloid angiopathy (CAA), possibly preceding hemorrhages. This exploratory study measured BBB leakage in vivo at the level of the leptomeningeal and small parenchymal vessels in patients with probable CAA. We hypothesized that BBB leakage from leptomeningeal and cortical small vessels would be higher in patients with CAA compared with controls and that leakage would be associated with hemorrhagic manifestations of CAA, that is, cortical superficial siderosis (cSS) and lobar cerebral microbleeds (CMBs). Patients with probable CAA without previous intracerebral hemorrhage and non-CAA patients with mild cognitive impairment from the memory clinic were recruited in this prospective observational exploratory study. Participants underwent 3T brain MRI with injection of a gadolinium-based contrast agent (Dotarem). Leakage from leptomeningeal vessels was assessed on postcontrast vs precontrast T2-fluid-attenuated inversion recovery as either focal or sulcal CSF enhancements. Dynamic contrast-enhanced scans were analyzed to quantify permeability-surface area product (PS): a measure of leakage from parenchymal small vessels. Fourteen patients with CAA (mean age 67.7 ± 9.0 years; 57% female) and 7 non-CAA patients with mild cognitive impairment (mean age 70.1 ± 6.5 years; 29% female) were recruited. Focal CSF enhancements were observed similarly often in patients with CAA (7 [50%]) and non-CAA controls (4 [57%], p = 0.98), whereas sulcal CSF enhancements were only seen in patients with CAA (5 [36%] vs 0 [0%]). In patients with CAA, focal and sulcal CSF enhancement counts were associated with higher cSS volume (B = 2.61, p = 0.003; B = 1.02, p = 0.02), but not with CMBs. PS was numerically higher in the cortex in patients with CAA (5.08 ± 4.02 × 10-4 min-1) than in non-CAA controls (1.29 ± 4.08 × 10-4 min-1, p = 0.07), but it was not associated with CMB count or cSS volume (p > 0.67). Leakage of gadolinium-based contrast agent through the BBB can be measured in vivo in CAA from the leptomeningeal vessels, and findings point to likely leakage from cortical small vessels as well. Leakage from leptomeningeal vessels was associated with cSS. Studies with follow-up data need to determine whether these measures could serve as a predictive biomarker in CAA.


  • Clinical Implementation of fMRI and EEG to Detect Cognitive Motor Dissociation

    by Yelena G. Bodien, Matteo Fecchio, Holly J. Freeman, William R. Sanders, Anogue Meydan, Phoebe K. Lawrence, John E. Kirsch, David Fischer, Joseph Cohen, Emily Rubin, et al.

    Cognitive motor dissociation (CMD) occurs when patients with severe brain injury follow commands on task-based functional MRI or EEG assessment despite demonstrating no behavioral evidence of language function. Recognizing the value of identifying patients with CMD, evidence-based guidelines published in the United States and Europe now recommend that these assessments are conducted as part of clinical care for select patients. We describe our institutionally supported approach for clinical assessment of CMD and report lessons learned so that other centers can more easily implement these evaluations. Among the key lessons are the need to consider ethical implications of CMD assessment; establish standardized local protocols for patient selection, data acquisition, analysis, and interpretation; and develop effective strategies for communication of test results. Independent validation of methods to assess CMD is not available. Our approach for clinical CMD assessment is intended to be flexible, allowing for iterative improvements as the evidence base grows.


  • The QIBA Profile for Dynamic Susceptibility Contrast MRI Quantitative Imaging Biomarkers for Assessing Gliomas

    by Mark S. Shiroishi, Bradley J. Erickson, Leland S. Hu, Daniel P. Barboriak, Lino Becerra, Laura C. Bell, Michael A. Boss, Jerrold L. Boxerman, Steven Cen, Lisa Cimino, et al.

    The Quantitative Imaging Biomarkers Alliance Profile for dynamic susceptibility contrast (DSC) MRI and its longitudinal claims for the precision of a DSC MRI–derived quantitative imaging biomarker to assess the relative cerebral blood volume changes in gliomas are summarized.


  • Evaluation of Ultrafast Wave–Controlled Aliasing in Parallel Imaging 3D-FLAIR in the Visualization and Volumetric Estimation of Cerebral White Matter Lesions

    by C. Ngamsombat, A.L.M. Gonçalves Filho, M.G.F. Longo, S.F. Cauley, K. Setsompop, J.E. Kirsch, Q. Tian, Q. Fan, D. Polak, W. Liu, et al.

    BACKGROUND AND PURPOSE: Our aim was to evaluate an ultrafast 3D-FLAIR sequence using Wave–controlled aliasing in parallel imaging encoding (Wave-FLAIR) compared with standard 3D-FLAIR in the visualization and volumetric estimation of cerebral white matter lesions in a clinical setting. MATERIALS AND METHODS: Forty-two consecutive patients underwent 3T brain MR imaging, including standard 3D-FLAIR (acceleration factor = 2, scan time = 7 minutes 50 seconds) and resolution-matched ultrafast Wave-FLAIR sequences (acceleration factor = 6, scan time = 2 minutes 45 seconds for the 20-channel coil; acceleration factor = 9, scan time = 1 minute 50 seconds for the 32-channel coil) as part of clinical evaluation for demyelinating disease. Automated segmentation of cerebral white matter lesions was performed using the Lesion Segmentation Tool in SPM. Student t tests, intraclass correlation coefficients, relative lesion volume difference, and Dice similarity coefficients were used to compare volumetric measurements among sequences. Two blinded neuroradiologists evaluated the visualization of white matter lesions, artifacts, and overall diagnostic quality using a predefined 5-point scale. RESULTS: Standard and Wave-FLAIR sequences showed excellent agreement of lesion volumes with an intraclass correlation coefficient of 0.99 and mean Dice similarity coefficient of 0.97 (SD, 0.05) (range, 0.84–0.99). Wave-FLAIR was noninferior to standard FLAIR for visualization of lesions and motion. The diagnostic quality for Wave-FLAIR was slightly greater than for standard FLAIR for infratentorial lesions (P < .001), and there were fewer pulsation artifacts on Wave-FLAIR compared with standard FLAIR (P < .001). CONCLUSIONS: Ultrafast Wave-FLAIR provides superior visualization of infratentorial lesions while preserving overall diagnostic quality and yields white matter lesion volumes comparable with those estimated using standard FLAIR. The availability of ultrafast Wave-FLAIR may facilitate the greater use of 3D-FLAIR sequences in the evaluation of patients with suspected demyelinating disease.


  • Evaluation of Ultrafast Wave-CAIPI MPRAGE for Visual Grading and Automated Measurement of Brain Tissue Volume

    by M.G.F. Longo, J. Conklin, S.F. Cauley, K. Setsompop, Q. Tian, D. Polak, M. Polackal, D. Splitthoff, W. Liu, R.G. González, et al.

    BACKGROUND AND PURPOSE: Volumetric brain MR imaging typically has long acquisition times. We sought to evaluate an ultrafast MPRAGE sequence based on Wave-CAIPI (Wave-MPRAGE) compared with standard MPRAGE for evaluation of regional brain tissue volumes. MATERIALS AND METHODS: We performed scan-rescan experiments in 10 healthy volunteers to evaluate the intraindividual variability of the brain volumes measured using the standard and Wave-MPRAGE sequences. We then evaluated 43 consecutive patients undergoing brain MR imaging. Patients underwent 3T brain MR imaging, including a standard MPRAGE sequence (acceleration factor [R] = 2, acquisition time [TA] = 5.2 minutes) and an ultrafast Wave-MPRAGE sequence (R = 9, TA = 1.15 minutes for the 32-channel coil; R = 6, TA = 1.75 minutes for the 20-channel coil). Automated segmentation of regional brain volume was performed. Two radiologists evaluated regional brain atrophy using semiquantitative visual rating scales. RESULTS: The mean absolute symmetrized percent change in the healthy volunteers participating in the scan-rescan experiments was not statistically different in any brain region for both the standard and Wave-MPRAGE sequences. In the patients undergoing evaluation for neurodegenerative disease, the Dice coefficient of similarity between volumetric measurements obtained from standard and Wave-MPRAGE ranged from 0.86 to 0.95. Similarly, for all regions, the absolute symmetrized percent change for brain volume and cortical thickness showed <6% difference between the 2 sequences. In the semiquantitative visual comparison, the differences between the 2 radiologists’ scores were not clinically or statistically significant. CONCLUSIONS: Brain volumes estimated using ultrafast Wave-MPRAGE show low intraindividual variability and are comparable with those estimated using standard MPRAGE in patients undergoing clinical evaluation for suspected neurodegenerative disease.


  • The Relationship between MRI Radiofrequency Energy and Function of Nonconditional Implanted Cardiac Devices: A Prospective Evaluation

    by Amir Ali Rahsepar, Stefan L. Zimmerman, Rozann Hansford, Michael A. Guttman, Valeria Castro, Diana McVeigh, John E. Kirsch, Henry R. Halperin, Saman Nazarian

    In patients with implanted cardiac devices who were undergoing MRI, we found no evidence of an association between parameters that characterize radiofrequency energy exposure to the patient and cha... Background The risks associated with MRI in individuals who have implanted cardiac devices are thought to arise from the interaction between the implanted device and static, gradient, and radiofreq...


  • Balanced Steady-State Free Precession Techniques Improve Detection of Residual Germ Cell Tumor for Treatment Planning

    by W.A. Mehan, K. Buch, M.F. Brasz, F.F.J. Simonis, S. MacDonald, S. Rincon, J.E. Kirsch, P. Caruso

    BACKGROUND AND PURPOSE: Identification of a partial/complete chemotherapy response in pediatric patients with intracranial germ cell tumors is clinically important for radiation treatment and management. Partial/complete response is conventionally determined on postcontrast MR imaging sequences. The purpose of this study was to assess the diagnostic utility of a balanced steady-state free precession sequence as an adjunct to standard MR imaging sequences for the detection of residual tumor in pediatric patients on postchemoreduction pre–radiation planning MR imaging. MATERIALS AND METHODS: This was a retrospective study of pediatric patients with intracranial germ cell tumors undergoing postchemotherapy, preradiotherapy MR imaging. Patients underwent 1.5T or 3T MR imaging with pre- and postcontrast T1WIs, T2WIs, and a balanced steady-state free precession sequence. Two neuroradiologists independently reviewed standard MR imaging sequences without the balanced steady-state free precession sequence, then with the balanced steady-state free precession sequence 1 week later. Assessment for partial/complete response was determined using Response Assessment in Neuro-Oncology criteria. A 5-point Likert scale scored the diagnostic confidence of the neuroradiologist rating each study without/with the balanced steady-state free precession sequence. Rates of residual disease concordance and diagnostic confidence levels without/with the balanced steady-state free precession sequence were calculated. RESULTS: Thirty-nine patients were included with 31 males and 8 females (mean age, 14.15 ± 4.26 years). Thirty-one patients had single-site disease; 8 patients had multisynchronous disease (47 sites in total). Compared to review of the standard MR sequences alone, the addition of the balanced steady state free precession sequence resulted in higher rates of tumor partial response categorization and greater diagnostic confidence levels (P < .001, P < .001). CONCLUSIONS: The balanced steady-state free precession sequence improves detection of residual chemotherapy-reduced intracranial germ cell tumors and increases diagnostic confidence of the neuroradiologist. The balanced steady-state free precession sequence may be an important adjunct to the standard MR imaging protocol for radiation planning.


  • MRI Techniques to Decrease Imaging Times in Children

    by Benjamin M. Kozak, Camilo Jaimes, John Kirsch, Michael S. Gee

    Several new commercially available and investigative techniques can significantly reduce MRI examination times in pediatric patients. Long acquisition times can limit the use of MRI in pediatric patients, and the use of sedation or general anesthesia is frequently necessary to facilitate diagnostic examinations. The use of sedati...


  • Using DICOM Metadata for Radiological Image Series Categorization: a Feasibility Study on Large Clinical Brain MRI Datasets

    by Romane Gauriau, Christopher Bridge, Lina Chen, Felipe Kitamura, Neil A. Tenenholtz, John E. Kirsch, Katherine P. Andriole, Mark H. Michalski, Bernardo C. Bizzo

    The growing interest in machine learning (ML) in healthcare is driven by the promise of improved patient care. However, how many ML algorithms are currently being used in clinical practice? While the technology is present, as demonstrated in a variety of commercial products, clinical integration is hampered by a lack of infrastructure, processes, and tools. In particular, automating the selection of relevant series for a particular algorithm remains challenging. In this work, we propose a methodology to automate the identification of brain MRI sequences so that we can automatically route the relevant inputs for further image-related algorithms. The method relies on metadata required by the Digital Imaging and Communications in Medicine (DICOM) standard, resulting in generalizability and high efficiency (less than 0.4 ms/series). To support our claims, we test our approach on two large brain MRI datasets (40,000 studies in total) from two different institutions on two different continents. We demonstrate high levels of accuracy (ranging from 97.4 to 99.96%) and generalizability across the institutions. Given the complexity and variability of brain MRI protocols, we are confident that similar techniques could be applied to other forms of radiological imaging.